PODD:NSD-Insulet Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 196.91

Change

-2.15 (-1.08)%

Market Cap

USD 13.80B

Volume

0.33M

Avg Analyst Target

USD 290.89 (+47.73%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Insulet Corporation (PODD) Stock Analysis:
Based on the Insulet Corporation stock forecasts from 10 analysts, the average analyst target price for Insulet Corporation is USD 290.89 over the next 12 months. Insulet Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Insulet Corporation is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Insulet Corporation’s stock price was USD 196.91. Insulet Corporation’s stock price has changed by +2.85% over the past week, -25.27% over the past month and -15.28% over the last year.

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-10.14 (-3.03%)

USD32.85B 171.14 77.12
ALGN Align Technology Inc

-1.32 (-0.48%)

USD21.71B 31.02 18.18
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

-0.37 (-0.15%)

USD11.58B 85.29 42.14
BRKR Bruker Corporation

-0.66 (-1.10%)

USD8.99B 33.27 17.75
SWAV ShockWave Medical Inc

+1.24 (+0.76%)

USD5.81B N/A 138.45
IART Integra LifeSciences Holdings ..

+0.39 (+0.66%)

USD4.93B 32.22 16.98
TNDM Tandem Diabetes Care Inc

-1.89 (-2.56%)

USD4.72B 307.71 186.72
IRTC iRhythm Technologies Inc

-6.04 (-4.34%)

USD3.93B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing PODD

Symbol Name Weight Mer Price(Change) Market Cap
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-0.03 (-0.10%)

USD0.06B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.99% 73% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.99% 73% C 44% F
Trailing 12 Months  
Capital Gain -13.80% 79% C+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.80% 79% C+ 55% F
Trailing 5 Years  
Capital Gain 385.00% 97% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 385.00% 97% A+ 95% A
Average Annual (5 Year Horizon)  
Capital Gain 48.08% 77% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.08% 77% C+ 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 39.73% 75% C 38% F
Risk Adjusted Return 121.02% 98% A+ 98% A+
Market Capitalization 13.80B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 829.42 5% F 2% F
Price/Book Ratio 29.34 4% F 3% F
Price / Cash Flow Ratio -202.68 96% A 92% A-
EV/EBITDA 84.91 16% F 8% F
Management Effectiveness  
Return on Equity 2.90% 80% B- 53% F
Return on Invested Capital 7.00% 83% B 67% D+
Return on Assets 4.02% 86% B 76% C
Debt to Equity Ratio 224.48% 9% F 10% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 8.21 23% F 15% F
Short Percent 6.18% 28% F 28% F
Beta 0.66 78% C+ 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.